Overview

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Status:
Terminated

Trial end date:
2017-02-23

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Sargramostim
Vaccines